List of Excipients in Branded Drug MYDRIACYL

Generic Drugs Containing MYDRIACYL

Company	Ingredient	NDC	Excipient
Alcon Laboratories Inc	tropicamide	0065-0355	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	tropicamide	0065-0355	EDETATE DISODIUM
Alcon Laboratories Inc	tropicamide	0065-0355	HYDROCHLORIC ACID
Alcon Laboratories Inc	tropicamide	0065-0355	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in MYDRIACYL?

# Of NDCs	Excipient
2	BENZALKONIUM CHLORIDE
2	EDETATE DISODIUM
2	HYDROCHLORIC ACID
2	SODIUM CHLORIDE

Mydriacyl Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Mydriacyl is a legacy tropicamide ophthalmic solution used for pharmacologic mydriasis and cycloplegia. Its commercial opportunity is unlikely to come from new-molecule exclusivity. The main opportunities are differentiated ophthalmic delivery systems, preservative reduction, unit-dose packaging, supply reliability, and line extensions that improve tolerability or clinic workflow. The reference formulation uses a conventional aqueous, preserved solution with benzalkonium chloride, boric acid, edetate disodium, sodium chloride, purified water, and pH adjustment agents.[1]

What is Mydriacyl and how is it regulated?

Mydriacyl contains tropicamide, an anticholinergic agent that produces short-duration pupil dilation. The U.S. product is marketed in 0.5% and 1% ophthalmic solution strengths. The approved label identifies the product as a sterile topical ophthalmic solution supplied in multidose containers.[1]

Attribute	Mydriacyl profile
Active ingredient	Tropicamide
Dosage form	Sterile ophthalmic solution
U.S. strengths	0.5% and 1%
Primary use	Mydriasis and cycloplegia
Route	Topical ocular
Preservative	Benzalkonium chloride, 0.01%
Regulatory pathway	Legacy FDA-approved drug product
Reference sponsor	Alcon Laboratories, Inc., according to FDA labeling
Key commercial setting	Optometry, ophthalmology, retinal examination and diagnostic clinics

Mydriacyl is a small-molecule ophthalmic product, not a biologic. Biosimilar risk therefore does not apply. Competitive pressure comes from generic tropicamide products, other mydriatic agents, compounded products where permitted, and clinic purchasing decisions.

What excipients are used in Mydriacyl?

The labeled inactive ingredients are benzalkonium chloride, boric acid, edetate disodium, sodium chloride, hydrochloric acid and/or sodium hydroxide, and purified water.[1]

Functional role of each excipient

Excipient	Formulation function	Commercial relevance
Benzalkonium chloride	Multidose preservative	Enables repeated use after opening but creates ocular-surface tolerability concerns
Boric acid	Buffering and tonicity contribution	Supports pH and osmolality control
Edetate disodium	Chelating agent	Can improve preservative performance by binding metal ions
Sodium chloride	Tonicity adjustment	Helps align the solution with ocular tolerability requirements
Hydrochloric acid/sodium hydroxide	pH adjustment	Supports chemical stability and comfort
Purified water	Vehicle	Provides the aqueous delivery medium

The formulation is operationally simple. That simplicity reduces manufacturing complexity but also limits differentiation unless a developer changes the preservative system, container, dose presentation, or delivery performance.

How strong is the Mydriacyl patent estate?

Mydriacyl has the profile of a mature, off-patent ophthalmic product. The commercial barrier is regulatory execution and manufacturing quality rather than an apparent active patent monopoly.

A current patent-rights analysis should distinguish three categories:

1. Patents covering tropicamide as a compound.
2. Patents covering Mydriacyl-specific formulations or delivery systems.
3. Patents covering later-developed preservative-free, sustained-release, or device-assisted products.

The original tropicamide product approvals date back decades, so basic compound and conventional solution protection would generally be expected to have expired. The FDA Orange Book should be checked for current patent listings associated with the specific reference product and approved strengths.[2] No active Orange Book patent or regulatory exclusivity should be assumed without a product-specific, current Orange Book review.

The practical implication is that a generic applicant can generally pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence where applicable, sterility, container-closure integrity, and compliance with ophthalmic quality requirements.

When does Mydriacyl lose exclusivity?

Mydriacyl’s core market protection has already matured. The product is not commercially protected by a contemporary new chemical entity exclusivity period. Any remaining market barriers are more likely to involve:

• Regulatory approval requirements.
• Sterile ophthalmic manufacturing capacity.
• Supplier qualification for pharmaceutical-grade excipients.
• Preservative and container-closure compatibility.
• Physician and clinic purchasing habits.
• Brand recognition in ophthalmic practices.
• Product availability and wholesaler contracts.

The distinction matters for investment analysis. A developer should not value Mydriacyl as a protected branded franchise solely because the brand remains marketed. Its economic position depends on product quality, distribution, service, and differentiated presentations.

What formulation patents could protect a new Mydriacyl product?

A new tropicamide product could pursue patent protection around a specific technical solution rather than the basic active ingredient. Potential claim areas include:

Preservative-free formulations

A single-use or preservative-free tropicamide formulation could target patients with ocular-surface sensitivity and institutions seeking to reduce exposure to benzalkonium chloride. Patentability would depend on a defined formulation, stability profile, packaging system, or manufacturing process.

A preservative-free product must address microbial protection through packaging and dose control rather than through a conventional multidose preservative. Relevant technologies include:

• Unit-dose blow-fill-seal containers.
• One-way valve multidose dispensers.
• Sterile, low-bioburden filling systems.
• Container designs that prevent backflow.
• Low-extractable and low-leachable polymer systems.

Reduced-benzalkonium formulations

A lower-preservative product could seek protection if it demonstrates a specific balance of antimicrobial efficacy, chemical stability, ocular tolerability, and container compatibility. A simple reduction in benzalkonium chloride concentration may not provide durable patent value unless supported by unexpected performance.

Viscosity-enhanced solutions

A modest increase in viscosity could prolong ocular residence time and potentially reduce drainage. Candidate excipients include hydroxypropyl methylcellulose, hypromellose, hydroxypropyl cellulose, carbomers, or other ophthalmic polymers. The tradeoff is important: higher viscosity can cause blurred vision, alter drop size, complicate sterilization, or slow administration in high-throughput clinics.

Enhanced-comfort formulations

Commercial differentiation may come from pH, osmolality, buffering capacity, and reduced surface-active excipients. Comfort claims would require controlled clinical or human-factor evidence. The product must preserve rapid onset and adequate pupil dilation, which limits how far a developer can modify the vehicle.

Combination mydriatic products

Tropicamide may be combined with phenylephrine in a fixed-dose ophthalmic product or co-packaged diagnostic regimen. Combination products can reduce the number of administration steps. They also create additional stability, compatibility, labeling, and dosing considerations. A combination is more likely to support commercial differentiation than a minor excipient change.

What are the best excipient opportunities for Mydriacyl?

The highest-value opportunities are concentrated in preservative exposure, packaging, and clinic efficiency.

1. Preservative-free unit-dose Mydriacyl

This is the clearest excipient and presentation opportunity. It could target:

• Patients with dry eye or ocular-surface disease.
• Repeated-use ophthalmic clinics.
• Pediatric and sensitive-patient populations.
• Practices seeking to minimize benzalkonium chloride exposure.
• Surgical and diagnostic settings requiring controlled single-patient dosing.

The principal disadvantages are higher packaging cost, more material consumption, and potentially lower gross margin per administered dose.

2. Preservative-reduced multidose packaging

A multidose bottle with reduced preservative burden could preserve clinic convenience while addressing tolerability concerns. The technical challenge is proving antimicrobial robustness throughout the in-use period.

3. Drop-size optimization

A smaller, consistent drop can reduce drug waste and improve dosing control. A drop-size program could involve nozzle geometry, polymer selection, surface tension control, and container design. This opportunity has a direct commercial link because ophthalmic drops often deliver more fluid than the conjunctival sac can retain.

4. Ready-to-use diagnostic kits

A branded kit could combine tropicamide with phenylephrine or include dosing aids, sterile accessories, and workflow labeling. The patent value would likely reside in the device, packaging, or regimen rather than in the conventional solution alone.

5. Supply-chain substitution

Excipient suppliers can pursue qualified alternatives for boric acid, sodium chloride, edetate disodium, and benzalkonium chloride. Dual sourcing can reduce manufacturing interruption risk. A supplier with validated low-endotoxin materials, tight particle controls, and reliable ophthalmic documentation may capture business even without a formulation patent.

What generic entry risks exist for Mydriacyl?

Generic entry risk is high because tropicamide is an established small molecule with conventional ophthalmic dosage forms. The likely generic development pathway involves a sterile solution with the same strength, route, dosage form, and active ingredient.

Risk area	Generic entrant exposure
Active ingredient	Low scientific risk because tropicamide is well characterized
Formulation	Moderate risk from pH, osmolality, preservative and stability requirements
Sterility	High operational importance
Packaging	Moderate risk from extractables, leachables and closure integrity
Clinical differentiation	Low for a standard generic; higher for preservative-free products
Supply	Moderate risk because ophthalmic manufacturing capacity is specialized
Pricing	High erosion risk in institutional and pharmacy channels

A Paragraph IV challenge would be relevant only if the Orange Book identifies an unexpired patent for the reference product. For a mature Mydriacyl product, the more probable commercial scenario is an ANDA launch based on ordinary generic competition rather than a patent litigation campaign.

What patent litigation and settlement agreements affect Mydriacyl?

No major contemporary patent-litigation or Paragraph IV settlement issue should be presumed for the conventional Mydriacyl formulation without a current docket and Orange Book review. The original product is too mature for a standard new-product exclusivity analysis.

If a later innovator develops a preservative-free, sustained-release, or device-enabled tropicamide product, litigation risk could shift to:

• Formulation patents.
• Container and dispenser patents.
• Use patents covering a diagnostic protocol.
• Manufacturing patents involving sterile filling or packaging.
• Patent disputes over combination therapy with phenylephrine.

A developer should separate the freedom-to-operate analysis for the active solution from the analysis for the delivery system. The latter may carry the more relevant current patent risk.

How does Mydriacyl compare with competing mydriatic products?

Mydriacyl competes with other tropicamide products, phenylephrine products, fixed-dose combinations, and alternative anticholinergic agents such as cyclopentolate.

Product category	Main advantage	Main limitation	Excipient opportunity
Tropicamide 0.5%	Lower concentration option	May provide less dilation in some settings	Comfort and preservative reduction
Tropicamide 1%	Stronger standard concentration	Greater exposure per administration	Drop-size and unit-dose optimization
Phenylephrine	Direct sympathomimetic mydriasis	Cardiovascular warnings and tolerability considerations	Low-volume delivery and combination packaging
Tropicamide/phenylephrine combination	Fewer administration steps	More complex stability and labeling	Co-formulation and dosing workflow
Cyclopentolate	Stronger cycloplegic effect	Longer duration and greater adverse-effect burden	Pediatric dosing and comfort improvements

The most defensible commercial position for a new Mydriacyl-related product is not necessarily a stronger concentration. A formulation that reduces clinic handling, minimizes preservative exposure, or improves dose reproducibility may have greater purchasing value.

What is the FDA and Orange Book status of Mydriacyl?

Mydriacyl is an FDA-approved prescription ophthalmic drug marketed in legacy 0.5% and 1% strengths. The FDA-approved labeling identifies the active ingredient, dosage forms, inactive ingredients, warnings, and administration instructions.[1]

The Orange Book remains the controlling source for current reference-product listings, therapeutic-equivalence information, patent listings, and exclusivity data.[2] Because Orange Book entries can change through approval actions, patent-listing updates, and product-status changes, a commercial diligence report should use the current edition rather than rely on historical records.

There is no biosimilar pathway for Mydriacyl. A competing product would generally be evaluated as a generic small-molecule ophthalmic drug or as a new drug if it introduces a materially different formulation, device, indication, or delivery system.

What commercial opportunities exist for Mydriacyl excipients and packaging?

The strongest opportunities are:

1. Preservative-free unit-dose tropicamide.
2. Low-benzalkonium or alternative-preservative multidose delivery.
3. Smaller, more consistent ophthalmic drops.
4. Tropicamide-phenylephrine combination presentations.
5. Contract manufacturing using validated sterile ophthalmic platforms.
6. Excipient dual sourcing and regional supply agreements.
7. Clinic-focused diagnostic kits.
8. Pediatric and ocular-surface-sensitive formulations.
9. Packaging with improved opening, dosing, and contamination control.
10. Geographic expansion through local sterile-fill partnerships.

Revenue exposure is difficult to quantify from public labeling because Mydriacyl-specific sales are not consistently disclosed separately from broader ophthalmic portfolios. The economic case should therefore be built from prescription volume, clinic utilization, generic price erosion, unit-dose conversion, and achievable reimbursement or purchasing premiums.

Geographically, the strongest opportunity is in markets with high optometry and ophthalmology throughput, established sterile ophthalmic manufacturing, and purchasing criteria that recognize preservative-free or workflow-enhanced products. Regulatory requirements will differ by jurisdiction, particularly for preservative systems, multidose in-use stability, and device-drug combinations.

Key Takeaways

• Mydriacyl is a mature tropicamide ophthalmic solution with limited apparent value from legacy molecule exclusivity.
• The labeled excipient system includes benzalkonium chloride, boric acid, edetate disodium, sodium chloride, purified water, and pH adjusters.
• Preservative-free unit-dose delivery is the clearest formulation and commercial opportunity.
• Drop-size control, contamination-resistant packaging, and fixed-dose combination products offer additional differentiation.
• Generic entry risk is high for conventional tropicamide solutions.
• Current patent risk should focus on later-developed formulations, devices, and manufacturing processes rather than the basic Mydriacyl solution.
• Biosimilar competition does not apply.
• The FDA Orange Book and current litigation records are required for definitive patent-listing and Paragraph IV conclusions.

FAQs About Mydriacyl Excipient and Patent Opportunities

Can benzalkonium chloride be removed from Mydriacyl?

Yes, but removal requires a new preservative-free packaging and sterility strategy. A conventional multidose bottle generally needs validated antimicrobial protection throughout its in-use period.

Is a preservative-free tropicamide product patentable?

Potentially. Patentability would depend on the specific formulation, packaging, stability, sterility, or performance claims. Preservative removal alone may not provide sufficient inventive distinction.

Would a tropicamide and phenylephrine product compete directly with Mydriacyl?

Yes. A fixed-dose or co-packaged product could compete by reducing administration steps, although it would require separate compatibility, stability, dosing, and regulatory analysis.

Do Mydriacyl patents prevent generic entry?

A generic applicant must review current Orange Book patent listings. For a mature conventional tropicamide product, the principal barriers are usually regulatory and manufacturing requirements rather than basic active-ingredient patent protection.

Which excipient strategy offers the strongest commercial premium?

Preservative-free unit-dose delivery has the strongest potential premium because it addresses ocular-surface tolerability and contamination control while creating a differentiated package and dosing system.

References

1. Alcon Laboratories, Inc. (n.d.). Mydriacyl (tropicamide ophthalmic solution USP) prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

3. United States Pharmacopeia. (2024). General chapter <771> ophthalmic products. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (1997). Guidance for industry: Ophthalmic drug products, quality considerations. Center for Drug Evaluation and Research.